MARKET

CBLI

CBLI

Cleveland Biolbs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
-0.24
-4.37%
Closed 16:00 05/10 EDT
OPEN
5.49
PREV CLOSE
5.49
HIGH
5.49
LOW
5.09
VOLUME
88.57K
TURNOVER
--
52 WEEK HIGH
10.97
52 WEEK LOW
1.430
MARKET CAP
81.21M
P/E (TTM)
-27.2727
1D
5D
1M
3M
1Y
5Y
2021 Global Bioterrorism Market is Expected to Thrive at Impressive CAGR by 2031| Altimmune, Bavarian Nordic, DynPort Vaccine Company (DVC)
marketresearch.biz · 4d ago
Bone Marrow Transplant Rejection Treatment Market Research 2027 Distribution Status by Players, Market Size Analysis and Forecast by Type and Application
The Express Wire · 04/15 11:27
Prostate Cancer Vaccines Market Size, Business Development Plans by Companies, Production Rate And Global Forecast 2026
Apr 15, 2021 (Market Stats News via COMTEX) -- A recent report provides crucial insights along with application based and forecast information in the Global...
Market Stats News · 04/15 10:50
Prostate Cancer Vaccines Market Share, Size Industry Trends, Global Competitors Strategy, Segments, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2026 Analysis
Apr 15, 2021 (The Expresswire) -- Global Prostate Cancer Vaccines Market Research Report has In-Depth Collective analysis of different factors that analyse...
The Express Wire · 04/15 05:47
Galectin Therapeutics, NexImmune leads healthcare gainers; LifeMD, CorMedix among major losers
Gainers: Galectin Therapeutics GALT +17%, NexImmune (NEXI) +16%, Kymera Therapeutics (KYMR) +15%, Nurix Therapeutics (NRIX) +15%, DBV Technologies (DBVT) +13%.Losers: LifeMD LFMD -24%, CorMedix CRMD -11%, Cleveland BioLabs (CBLI) -9%, Avenue Therapeutics (...
Seekingalpha · 04/14 15:04
Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532
The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticalsBUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Clev...
ACCESSWIRE · 04/14 12:22
Cleveland BioLabs Joint Venture Genome Protection Highlights Publication Of TLR5 Agonist, GP532 In Communications Biology
Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and
Benzinga · 04/14 12:13
Biodefense Market Share, Size, Business Analysis, Key Players, Market Opportunity, Development, Demand, Growth, Overview, Trends and Forecast 2021-2024
Apr 14, 2021 (The Expresswire) -- Global "Biodefense Market" report covers the present status of Market Share, CAGR, Revenue, Gross Market and the growth...
The Express Wire · 04/14 06:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBLI. Analyze the recent business situations of Cleveland Biolbs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 623.22K
% Owned: 4.03%
Shares Outstanding: 15.47M
TypeInstitutionsShares
Increased
0
0
New
4
348.26K
Decreased
3
43.83K
Sold Out
2
26.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
Lea Verny
President
Langdon Miller
Chief Executive Officer/Chief Financial Officer/Vice President - Finance
Christopher Zosh
Chief Scientific Officer
Andrei Gudkov
Independent Director
Alexander Andryushechkin
Independent Director
Anna Evdokimova
Independent Director
Ivan Fedyunin
Independent Director
Randy Saluck
Independent Director
Daniil Talyanskiy
No Data
About CBLI
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Webull offers kinds of Cleveland BioLabs, Inc. stock information, including NASDAQ:CBLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBLI stock methods without spending real money on the virtual paper trading platform.